Vergelijking

Glepaglutide vs. Pasireotid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

geen gegevens

396091-73-9

Molecuulmassa

geen gegevens

1047.21 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Glepaglutide	Pasireotid
Duitsland	Niet goedgekeurd	Op recept
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Glepaglutide

Volledige vermelding →

Pasireotid

Volledige vermelding →

Frequently asked questions

What is the difference between Glepaglutide and Pasireotid?: Glepaglutide is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Pasireotid?: The highest available evidence level is "Humane RCT" for Glepaglutide and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Pasireotid in Germany and the United States?: Duitsland: Glepaglutide — Niet goedgekeurd, Pasireotid — Op recept. Verenigde Staten: Glepaglutide — Niet goedgekeurd, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Pasireotid

Duitsland

Niet goedgekeurd

Op recept

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Glepaglutide and Pasireotid?

Glepaglutide is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Pasireotid?

The highest available evidence level is "Humane RCT" for Glepaglutide and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Pasireotid in Germany and the United States?

Duitsland: Glepaglutide — Niet goedgekeurd, Pasireotid — Op recept. Verenigde Staten: Glepaglutide — Niet goedgekeurd, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.